The University of Southampton
University of Southampton Institutional Repository

Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study

Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study
Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study
Background: Panic disorder (PD) is a prevalent and impairing anxiety disorder with previous reports suggesting that the longer the condition remains untreated, the greater the likelihood of nonresponse. However, patients with PD may wait for years before receiving a guideline-recommended pharmacological treatment. The widespread prescription of benzodiazepines (BDZ) for managing anxiety symptoms and disorders might delay the administration of pharmacotherapy according to guidelines (eg, selective serotonin reuptake inhibitors, SSRIs). The present study aimed to determine the mean duration of untreated illness (DUI) in a sample of PD patients, to quantify and compare DUI-SSRI to DUI-BDZ, and to compare findings with those from previous investigations.
Methods: Three hundred and fourteen patients with a Diagnostic and Statistical Manual of Mental Disorders, fifth edition diagnosis of PD were recruited from an Italian outpatient psychotherapy unit, and epidemiological and clinical variables were retrieved from medical records. Descriptive statistical analyses were undertaken for sociodemographic and clinical variables, Wilcoxon matched-pair signed rank test was applied to compare the distribution of DUI-SSRI vs DUI-BDZ, and Welch's t test was performed to compare findings with those from previous studies.
Results: The mean DUI-SSRI of the total sample was 64.25 ± 112.74 months, while the mean DUI-BDZ was significantly shorter (35.09 ± 78.62 months; P < 0.0001). A significantly longer DUI-SSRI, compared to findings from previous studies, was also observed.
Conclusions: The present results confirm a substantial delay in implementing adequate pharmacological treatments in patients with PD, and highlight the discrepancy between recommendations from international treatment guidelines and common clinical practice in relation to BDZ prescription.
Psychopharmacology, anxiety disorders, duration of untreated illness, panic disorder, treatment
1092-8529
1-7
Piccoli, Eleonora
cfdd6eba-ce25-4059-9e49-49a51b2d2145
Bergamaschini, Irma
7f023de3-f426-4d0f-bfbe-84f217123195
Molteni, Laura
1b55e314-9610-44cc-95bb-9613be57f375
Vanzetto, Simone
eeaa28be-91c5-46a9-b30d-4576920b7767
Varinelli, Alberto
a5633f26-d7c9-4553-989d-7a9f34c590df
Viganò, Caterina
e17dac88-b25b-4588-957f-b5d063dfce2b
Catania, Gabriele
52ac37fc-e3c4-4a4f-a4ee-3fa8096343d3
Baldwin, David S
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Domschke, Katharina
7c6913b2-7906-4a9e-b3ee-003437dce668
Dell'Osso, Bernardo
92b13aa3-d1bb-46d8-83cd-ed220cf450b5
Piccoli, Eleonora
cfdd6eba-ce25-4059-9e49-49a51b2d2145
Bergamaschini, Irma
7f023de3-f426-4d0f-bfbe-84f217123195
Molteni, Laura
1b55e314-9610-44cc-95bb-9613be57f375
Vanzetto, Simone
eeaa28be-91c5-46a9-b30d-4576920b7767
Varinelli, Alberto
a5633f26-d7c9-4553-989d-7a9f34c590df
Viganò, Caterina
e17dac88-b25b-4588-957f-b5d063dfce2b
Catania, Gabriele
52ac37fc-e3c4-4a4f-a4ee-3fa8096343d3
Baldwin, David S
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Domschke, Katharina
7c6913b2-7906-4a9e-b3ee-003437dce668
Dell'Osso, Bernardo
92b13aa3-d1bb-46d8-83cd-ed220cf450b5

Piccoli, Eleonora, Bergamaschini, Irma, Molteni, Laura, Vanzetto, Simone, Varinelli, Alberto, Viganò, Caterina, Catania, Gabriele, Baldwin, David S, Domschke, Katharina and Dell'Osso, Bernardo (2021) Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study. CNS Spectrums, 1-7. (doi:10.1017/S1092852921000869).

Record type: Article

Abstract

Background: Panic disorder (PD) is a prevalent and impairing anxiety disorder with previous reports suggesting that the longer the condition remains untreated, the greater the likelihood of nonresponse. However, patients with PD may wait for years before receiving a guideline-recommended pharmacological treatment. The widespread prescription of benzodiazepines (BDZ) for managing anxiety symptoms and disorders might delay the administration of pharmacotherapy according to guidelines (eg, selective serotonin reuptake inhibitors, SSRIs). The present study aimed to determine the mean duration of untreated illness (DUI) in a sample of PD patients, to quantify and compare DUI-SSRI to DUI-BDZ, and to compare findings with those from previous investigations.
Methods: Three hundred and fourteen patients with a Diagnostic and Statistical Manual of Mental Disorders, fifth edition diagnosis of PD were recruited from an Italian outpatient psychotherapy unit, and epidemiological and clinical variables were retrieved from medical records. Descriptive statistical analyses were undertaken for sociodemographic and clinical variables, Wilcoxon matched-pair signed rank test was applied to compare the distribution of DUI-SSRI vs DUI-BDZ, and Welch's t test was performed to compare findings with those from previous studies.
Results: The mean DUI-SSRI of the total sample was 64.25 ± 112.74 months, while the mean DUI-BDZ was significantly shorter (35.09 ± 78.62 months; P < 0.0001). A significantly longer DUI-SSRI, compared to findings from previous studies, was also observed.
Conclusions: The present results confirm a substantial delay in implementing adequate pharmacological treatments in patients with PD, and highlight the discrepancy between recommendations from international treatment guidelines and common clinical practice in relation to BDZ prescription.

Text
CNS-2021-finaldraft - Accepted Manuscript
Download (446kB)

More information

Accepted/In Press date: 14 September 2021
Published date: 5 November 2021
Additional Information: Publisher Copyright: © The Author(s), 2021. Published by Cambridge University Press.
Keywords: Psychopharmacology, anxiety disorders, duration of untreated illness, panic disorder, treatment

Identifiers

Local EPrints ID: 453086
URI: http://eprints.soton.ac.uk/id/eprint/453086
ISSN: 1092-8529
PURE UUID: 89f12742-d325-4a00-b62e-28849623bc89
ORCID for David S Baldwin: ORCID iD orcid.org/0000-0003-3343-0907

Catalogue record

Date deposited: 07 Jan 2022 17:52
Last modified: 17 Mar 2024 06:56

Export record

Altmetrics

Contributors

Author: Eleonora Piccoli
Author: Irma Bergamaschini
Author: Laura Molteni
Author: Simone Vanzetto
Author: Alberto Varinelli
Author: Caterina Viganò
Author: Gabriele Catania
Author: David S Baldwin ORCID iD
Author: Katharina Domschke
Author: Bernardo Dell'Osso

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×